STOCK TITAN
  1. Home
  2. News
  3. NTRA

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.

Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.

Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.

News

Natera Announces Real-World Data Collaboration with Merck

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) has entered into an agreement with Merck to utilize Natera’s real-world database (RWD) for oncology research. The RWD contains de-identified clinical and genomic data from over 100,000 early- and late-stage cancer patients tested with Signatera™. Pharmaceutical companies can use the RWD to advance drug development programs across early-stage and metastatic settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
none
-
News

Natera Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) reported a 27% increase in total revenues in Q3 2023, reaching $268.3 million, with product revenues growing approximately 33%. The company reduced cash burn by 66% and processed approximately 626,000 tests, a 21% increase from the same period last year. Natera raised its 2023 annual revenue guidance to $1.035 billion to $1.05 billion and gross margin to 43% to 44%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
earnings
-
News

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) announced the TREAT ctDNA study to evaluate elacestrant in early breast cancer patients with molecular relapse using Signatera. The study aims to assess whether elacestrant can delay distant metastasis or death compared to standard therapy in ER+/HER2- patients. Approximately 1,900 patients will be screened at 120+ sites in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
clinical trial
News

Natera to Participate in November Investor Conferences

Rhea-AI Summary
Natera, Inc. (NASDAQ: NTRA) will be participating in investor conferences on November 14 and 28, with live webcasts and audio archives accessible through their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
-
News

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

Rhea-AI Summary
Natera, Inc. announced the publication of initial results from RenaCARE, a study on genetic testing in chronic kidney disease (CKD) patients. The study found that 1 in 5 CKD patients had a positive genetic finding, with 48.8% receiving a new or reclassified diagnosis and 34% receiving disease subtype information. Additionally, 90.7% of positive patients had a change in management, including 32.9% with a change in treatment plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
News

Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients

Rhea-AI Summary
Natera, Inc. announces updated data from the GALAXY arm of the CIRCULATE-Japan trial at the ESMO Congress, showcasing the ability of the Signatera MRD test in identifying patients with resectable colorectal cancer who are at an increased risk of recurrence and predicting who are most likely to benefit from adjuvant chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Natera to Report its Third Quarter 2023 Results on November 8

Rhea-AI Summary
Natera, Inc. to release third quarter 2023 financial results on November 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences earnings
-
News

Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Rhea-AI Summary
Natera to present new data on its MRD test at the 2023 ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
-
News

New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Rhea-AI Summary
Natera's Signatera test shows 82% pre-treatment detection and 100% longitudinal sensitivity and specificity in detecting disease progression in lung cancer patients treated with radiotherapy, potentially enabling customized treatment strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
News

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Rhea-AI Summary
The United States Supreme Court has denied CareDx's petition for certiorari in a patent infringement lawsuit against Natera, confirming the invalidity of the asserted patents. This decision upholds previous rulings by the District Court and the Court of Appeals. It effectively terminates any existing claims brought by CareDx against Natera regarding these patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
Stock NTRA logo
Natera Inc

Nasdaq:NTRA

NTRA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NTRA Stock Data

20.88B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN